TPO and non-small cell lung carcinoma: assessed the efficacy and safety of PD-1 blockade in 137 patients with advanced NSCLC based on the existence of preexisting autoimmune markers such as rheumatoid factor, ANA, antithyroglobulin, and anti-thyroid peroxidase (11).